RedHill Biopharma (RDHL) Price to Sales (2013 - 2023)

RedHill Biopharma (RDHL) has reported Price to Sales for 11 consecutive years, with 1034.46 the latest figure, recorded in Q2 2023.

• On a quarterly basis, Price to Sales fell 58.59% year-over-year to 1034.46 in Q2 2023; TTM through Jun 2023 was 51.98, a 91.48% decrease from a year earlier, with the FY2025 full-year figure at 53.17, down 73.42% from the prior year.
• Price to Sales was 1034.46 for Q2 2023 at RedHill Biopharma, down from 1759.47 in the prior quarter.
• Over five years, Price to Sales peaked at 151298.43 in Q1 2020 and troughed at 677.46 in Q4 2022.
• A 5-year average of 39428.42 and a median of 11796.66 in 2020 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales surged 197.39% in 2019 and sank 90.97% in 2021, its largest moves.
• Over 5 years, Price to Sales stood at 134645.45 in 2019, then tumbled by 89.26% to 14456.78 in 2020, then sank by 57.4% to 6158.55 in 2021, then slumped by 89.0% to 677.46 in 2022, then soared by 52.7% to 1034.46 in 2023.
• The last three Price to Sales figures came in at 1034.46 (Q2 2023), 1759.47 (Q1 2023), and 677.46 (Q4 2022), per Business Quant data.